Rongchang Bio starts construction of biopharmaceutical R&D and industrialization project in Yantai

Rongchang Bio held a groundbreaking ceremony for its biopharmaceutical R&D and industrialization project in Yantai, Shandong, with an investment of 5 billion yuan, to be completed by 2023, producing 6 million units of Telitacicept and 3 million units of Disitamab vedotin annually.

“该项目由荣昌生物投资50亿元，2023年总体建成启用，总产值可达170亿元，用于“泰它西普”、“艾地希”产品上市后的产业化运营，达产后可实现年产“泰它西普”600万支、年产“艾地希”300万支。”jiaodong.net

• 1 source
• jiaodong.net山东省重点项目网上开工仪式在荣昌生物医药园举行 财经新闻 烟台新闻网 胶东在线 国家批准的重点新闻网站Feb 19, 2020

Summarized from public sources; check the original articles before acting on it.